Company Overview and News

4
Biotech Analysis Central Pharma News: Celgene's Protocol Change, Roche's BLA For Herceptin, Amgen's Resubmission For Osteoporosis

2018-07-16 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
AMGN BLUE HALO CELG BLUE

52
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon and welcome to the Halozyme Therapeutics First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this call is being recorded.
HALO

52
Halozyme Therapeutics, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-10 seekingalpha
The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2018 Q1 earnings call.
HALO

55
HALO / Halozyme Therapeutics, Inc. S-8

2018-05-10 sec.gov
Document As filed with the Securities and Exchange Commission on May 10, 2018
HALO

53
52
107
LogMeIn started at buy with $145 stock price target at Mizuho

2018-04-02 marketwatch
LogMeIn Inc. shares fell more than 5% in the extended session Thursday after the company missed revenue expectations and issued weaker-than-expected first-quarter guidance. The company reported fourth-quarter net income of $93.3 million, or $1.74 a share, compared with $1.9 million, or 7 cents a share, in the year-ago period. Adjusted earnings were $1.20 a share. Revenue rose to $279.9 million from $88 million in the year-ago period.
OCUL LOGM ALKS HALO EEFT PGRE MANH HDP POWI

52
HALO: Halozyme Therapeutics Analysis and Research Report

2018-02-13 - Asif

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. The company's proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. The company exploit its technology and expertise using a two pillar strategy that the company believe enables it to manage risk and cost by: (1) developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing its technology to biopharmaceutical companies to collaboratively develop products that combine its technology with the collaborators’ proprietary compounds. The majority of its approved product and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. The company's proprietary development pipeline con...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to HALO / Halozyme Therapeutics, Inc. on message board site Silicon Investor.

CEPHALON LTD u0026 THEIR UNSAFE ZACIN CREAM CEPH - CEPHALON
BS Bernanke (Ben Shalom Bernanke), 14th Fed Chairman HALO Technologies Holdings, Inc
Modified Athalon for Overclocking? Cephalon (CEPH) Coiled u0026 Ready
CUSIP: 40637H109